Stay updated with breaking news from Evaluate Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3...
/PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3...
75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI)Severe CVI Impacts Approximately 2.4 million
Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario. BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to ...
Share this article Share this article FORT COLLINS, Colo., March 16, 2021 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating next generation immune therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2, the virus that causes COVID-19. CYTO-205 is designed to modulate immune system function, decrease elevated inflammatory responses associated with viral...